Effect of fluoridation of hydroxyapatite in hydroxyapatite-polycaprolactone composites on osteoblast activity.
Fluorine was administered to a system of hydroxyapatite (HA)/polycaprolactone (PCL) ceramic-polymer bioactive composites for applications as hard tissue regeneratives. The HA was fluoridated at different levels (5%, 25%, 50% and 75%) in order to produce the fluor-hydroxyapatite (FHA)/PCL composites. The osteoblastic cellular responses to the composites were examined in terms of the cell attachment, proliferation and differentiation as well as the expression of bone-associated genes. The amount of fluorine released from the composites was controlled by changing the degree of fluoridation, and the cellular responses were strongly influenced by the level of fluoridation. The MG63 cells on the FHA-PCL attached and proliferated at a similar level to those on HA-PCL. However, the fluoridation of HA increased significantly the alkaline phosphatase (ALP) activity and osteocalcin (OC) production by the cells on the composites, which was measured by an enzymatic assay. Moreover, the gene expression level of ALP and OC in the cells was up regulated on the FHA-PCL, which was confirmed semi-quantitatively by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. These findings on the fluorine-administered biological composites (FHA-PCL) suggested that fluorine plays a significant role in stimulating the bone derived cellular activity, and the FHA-PCL composites have high potential for use as hard tissue regeneratives.
Kim
Hae-Won
HW
School of Materials Science and Engineering, Seoul National University, Seoul 151-742, Korea. hwkim@snu.ac.kr
Lee
Eun-Jung
EJ
Kim
Hyoun-Ee
HE
Salih
Vehid
V
Knowles
Jonathan C
JC
D001826:Body Fluids / Q000737:chemistry; D018786:Bone Substitutes / Q000737:chemistry / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D004058:Diffusion; D016503:Drug Delivery Systems / Q000379:methods; D005461:Fluorine / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D006882:Hydroxyapatites / Q000737:chemistry* / Q000494:pharmacology; D008420:Manufactured Materials / Q000032:analysis; D008422:Materials Testing; D010006:Osteoblasts / Q000187:drug effects* / Q000502:physiology*; D011091:Polyesters / Q000737:chemistry*
D018786:Bone Substitutes; D006882:Hydroxyapatites; D011091:Polyesters; C016240:polycaprolactone; D005461:Fluorine; C028869:fluor-hydroxylapatite